Company release, Inside information

12 April 2024 at 12.45 p.m. (EEST)

Nightingale Health supplements the Company release published on 12 April 2024 at 7:15 a.m. (EEST) with information regarding the impact of the agreement with Kaiser Foundation Health Plan, Inc. on Nightingale Health’s revenue and profit.

As additional information to the previous Company release, the company estimates, that the agreement will have no impact on the company’s revenue and profit in the current financial year ending 30 June 2024, or the impact on revenue and profit in the current financial year will be very small.

The company estimates that the agreement’s impact on the revenue and profit in the next financial year from 1 July 2024 to 30 June 2025 will be significant in relation to the company’s current revenue level. However, the timing of the revenue recognition depends on blood sample shipment and analysis schedules, and is uncertain.

The impact of the agreement on the company’s profit is positive.

For further information, please contact:

Teemu Suna, CEO

Certified advisor:

Oaklins Merasco Ltd, tel. +358 9 6129 670

About Nightingale Health

Nightingale Health is The Preventative Health Company. Staying healthy is one of the top priorities in human life. Our health has a profound impact on our quality of life, and it’s also strongly connected to the lives of those close to us. Nightingale Health enables prevention by combining the power of our in-house developed, advanced blood analysis technology with unprecedented access to global health repositories and world-leading medical research. With this combination, we go beyond the traditional healthcare and wellbeing tools: We provide the scientific connection to multiple health and disease outcomes and the ability to predict future healthy years.

Nightingale Health operates globally with a parent company in Finland and seven subsidiaries in countries such as Japan, the United States, Singapore, and the United Kingdom. Nightingale Health has customers in more than 34 countries in the healthcare and medical research sectors. The company’s technology is being used in many of the world’s leading health initiatives, such as the UK Biobank, and over 600 peer-reviewed publications validate the technology. The company’s Series B shares are listed on the First North Growth Market Finland marketplace. Read more: